184 related articles for article (PubMed ID: 21235599)
1. JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis.
Qi X; Hu F; Yang Z; Han G; Fan D
Aliment Pharmacol Ther; 2011 Feb; 33(4):495-6; author reply 496-7. PubMed ID: 21235599
[No Abstract] [Full Text] [Related]
2. JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes.
Kanellopoulou T; Alexopoulou A; Koskinas J
Aliment Pharmacol Ther; 2011 Jun; 33(12):1382-3. PubMed ID: 21569067
[No Abstract] [Full Text] [Related]
3. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
[No Abstract] [Full Text] [Related]
4. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
[No Abstract] [Full Text] [Related]
5. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
[No Abstract] [Full Text] [Related]
6. The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis.
Orr DW; Patel RK; Lea NC; Westbrook RH; O'Grady JG; Heaton ND; Pagliuca A; Mufti GJ; Heneghan MA
Aliment Pharmacol Ther; 2010 Jun; 31(12):1330-6. PubMed ID: 20331577
[TBL] [Abstract][Full Text] [Related]
7. Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms.
Dong B; Zhang Y; Fu X; Wang G
Thromb Res; 2012 May; 129(5):664-5. PubMed ID: 22197451
[No Abstract] [Full Text] [Related]
8. JAK2V617F mutation in patients with splanchnic vein thrombosis.
Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N
Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis.
De Stefano V; Fiorini A; Rossi E; Za T; Chiusolo P; Sica S; Leone G
Hepatology; 2007 Mar; 45(3):831-2; author reply 832-3. PubMed ID: 17326212
[No Abstract] [Full Text] [Related]
10. Inferior vena cava thrombosis and its relationship with the JAK2V617F mutation and chronic myeloproliferative disease.
Linnemann B; Kraft C; Roskos M; Zgouras D; Lindhoff-Last E
Thromb Res; 2012 Jun; 129(6):720-4. PubMed ID: 21982959
[TBL] [Abstract][Full Text] [Related]
11. [Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F].
Fama A; Rago A; Gioiosa F; Marzano C; Latagliata R; Mammì C; Laganà C; D'Elia GM; Bizzoni L; Trasarti S; Ferretti A; Breccia M; Riggio O; Tafuri A
Clin Ter; 2010; 161(2):169-71. PubMed ID: 20499034
[TBL] [Abstract][Full Text] [Related]
12. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.
Villani L; Bergamaschi G; Primignani M; Rosti V; Carolei A; Poletto V; Catarsi P; Spolverini A; Vannucchi AM; Barosi G
Leuk Res; 2012 Jan; 36(1):e7-9. PubMed ID: 21890200
[No Abstract] [Full Text] [Related]
13. JAK2V617F mutation in patients with thrombosis: to screen or not to screen?
Xavier SG; Gadelha T; Rezende SM; Zalcberg IR; Spector N
Int J Lab Hematol; 2011 Apr; 33(2):117-24. PubMed ID: 21118380
[TBL] [Abstract][Full Text] [Related]
14. JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?
Janssen HL; Leebeek FW
Hepatology; 2006 Dec; 44(6):1391-3. PubMed ID: 17133464
[No Abstract] [Full Text] [Related]
15. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation.
Grandone E; Colaizzo D; Tiscia GL; Vergura P; Chinni E; Iannaccone L; Antinolfi I; Guardascione MA; Margaglione M
Thromb Haemost; 2008 Mar; 99(3):640-2. PubMed ID: 18327418
[No Abstract] [Full Text] [Related]
16. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
Foucar CE; Stein BL
JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
[No Abstract] [Full Text] [Related]
17. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.
Qi X; Yang Z; Bai M; Shi X; Han G; Fan D
Aliment Pharmacol Ther; 2011 May; 33(10):1087-103. PubMed ID: 21395632
[TBL] [Abstract][Full Text] [Related]
19. Calreticulin mutations and their importance in splanchnic vein thrombosis.
Sekhar M; Patch D; Austen B; Howard J; Hart S
Br J Haematol; 2016 Jul; 174(1):158-60. PubMed ID: 26358155
[No Abstract] [Full Text] [Related]
20. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.
De Stefano V; Rossi E; Za T; Chiusolo P; Leone G
Thromb Haemost; 2008 Jun; 99(6):1121. PubMed ID: 18521519
[No Abstract] [Full Text] [Related]
[Next] [New Search]
